With apologies to pigofsteel for lifting this from another...

With apologies to pigofsteel for lifting this from another forum:

From Southern Cross Equities report on Phosphagenics - credibility to cellulite reducing cream:

"Why POH thinks in can succeed where Metabolic failed. POHs basic thinking
on AOD9604 is that the drug failed as an obesity therapy because it was made
orally available, which likely reduced bioavailability and also potentially resulted in
protein denaturisation in the gastrointestinal tract which would have reduced the
drugs activity. POH now wants to try transdermal delivery via a cosmetic cream,
which would allow the drug to be delivered directly into subcutaneous fat tissue
without alteration130. A cellulite and subcutaneous fat indication would likely
require less in the way of trial data to get on the market, since no therapeutic
claims would be made and data would be mainly to substantiate label claims.
AOD9604 was safe and well tolerated in Metabolics Phase IIb trial.
The time to market is fairly short. POH believes that, should the research be
successful, a commercial cosmetic cream can be launched by the first half of
calendar 2011. The development costs of this product will likely be mild only
$100,000 for pre-clinicals and a short clinical trial before product release."

Of course, if Phosphagenics succeeds with this application, CZD will be a huge beneficiary via royalties.